Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials

By sjmartinez • July 14, 2023

Theodore DA, Branche AR, Zhang L, Graciaa DS, Choudhary M, Hatlen TJ, Osman R, Babu TM, Robinson ST, Gilbert PB, Follmann D, Janes H, Kublin JG, Baden LR, Goepfert P, Gray GE, Grinsztejn B, Kotloff KL, Gay CL, Leav B, Miller J, Hirsch I, Sadoff J, Dunkle LM, Neuzil KM, Corey L, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y; COVID-19 Prevention Network (CoVPN). Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials. JAMA Netw Open. 2023 Jul 3;6(7):e2323349. doi: 10.1001/jamanetworkopen.2023.23349. PMID: 37440227.

Tags: Infectious Diseases, Publications

Related Posts

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson[...]

Clinical consequences of delaying implementation of long-acting antiretroviral therapy for people with HIV and persistent viremia in the US

Pei PP, Jones M, Hu R, Chen W, Sax PE, Pandya A, Gandhi M, Eron JJ, Currier JS, Wilkin TJ, Reddy KP, Qoshe L, Hyle[...]

A New Approach to In Vivo Transformation of Killer T cells

Rodriguez N, Hofmann C, Yang OO, Gelbart WM. A New Approach to In Vivo Transformation of Killer T cells. J Mol Biol. 2025 Aug 1:169369.[...]